SYSTEMIC CARNITINE DEFICIENCY GENE AND USES THEREOF
    2.
    发明申请
    SYSTEMIC CARNITINE DEFICIENCY GENE AND USES THEREOF 审中-公开
    系统性心肌缺血基因及其用途

    公开(公告)号:US20120129184A1

    公开(公告)日:2012-05-24

    申请号:US13197488

    申请日:2011-08-03

    IPC分类号: C12Q1/68 C12Q1/02 G01N33/566

    摘要: The gene responsible for systemic carnitine deficiency was found to be the OCTN2 gene involved in the transportation of organic cations. This invention enables tests for this disease by detecting whether or not the OCTN2 gene has a mutation. Furthermore, systemic carnitine deficiency can be treated using the normal OCTN2 gene and its protein.

    摘要翻译: 发现引起全身肉碱缺乏的基因是涉及有机阳离子运输的OCTN2基因。 本发明能够通过检测OCTN2基因是否具有突变来测试该疾病。 此外,可以使用正常的OCTN2基因及其蛋白质治疗系统性肉碱缺乏症。

    Transporter genes OATP-B, C, D, and E
    4.
    发明授权
    Transporter genes OATP-B, C, D, and E 失效
    转运蛋白基因OATP-B,C,D和E

    公开(公告)号:US08748128B2

    公开(公告)日:2014-06-10

    申请号:US12759605

    申请日:2010-04-13

    IPC分类号: C12P21/00

    摘要: Four novel transporter genes were successfully cloned by screening novel transporter genes based on the human OATP transporter gene sequence. These transporters are useful in the development of drugs by taking advantage of the activity of transporting biological substances and various drugs. It was also found that these transporter genes have single nucleotide polymorphisms (SNP). Gene diagnosis based on the polymorphisms (such as SNP) in these transporter genes enables one to judge, for example, the efficacy of a drug therapy.

    摘要翻译: 通过筛选基于人OATP转运蛋白基因序列的新型转运蛋白基因,成功克隆了四种新型转运蛋白基因。 这些转运蛋白通过利用运输生物物质和各种药物的活性,可用于开发药物。 还发现这些转运蛋白基因具有单核苷酸多态性(SNP)。 基于这些转运蛋白基因多态性(例如SNP)的基因诊断使得人们能够判断药物疗法的功效。

    TRANSPORTER GENES OATP-B, C, D, AND E
    5.
    发明申请
    TRANSPORTER GENES OATP-B, C, D, AND E 失效
    运输基因OATP-B,C,D和E

    公开(公告)号:US20100196960A1

    公开(公告)日:2010-08-05

    申请号:US12759605

    申请日:2010-04-13

    摘要: Four novel transporter genes were successfully cloned by screening novel transporter genes based on the human OATP transporter gene sequence. These transporters are useful in the development of drugs by taking advantage of the activity of transporting biological substances and various drugs. It was also found that these transporter genes have single nucleotide polymorphisms (SNP). Gene diagnosis based on the polymorphisms (such as SNP) in these transporter genes enables one to judge, for example, the efficacy of a drug therapy.

    摘要翻译: 通过筛选基于人OATP转运蛋白基因序列的新型转运蛋白基因,成功克隆了四种新型转运蛋白基因。 这些转运蛋白通过利用运输生物物质和各种药物的活性,可用于开发药物。 还发现这些转运蛋白基因具有单核苷酸多态性(SNP)。 基于这些转运蛋白基因多态性(例如SNP)的基因诊断使得人们能够判断药物疗法的功效。

    Transporter genes OATP-B, C, D, and E
    6.
    发明申请
    Transporter genes OATP-B, C, D, and E 审中-公开
    转运蛋白基因OATP-B,C,D和E

    公开(公告)号:US20060121523A1

    公开(公告)日:2006-06-08

    申请号:US11337061

    申请日:2006-01-19

    摘要: Four novel transporter genes were successfully cloned by screening novel transporter genes based on the human OATP transporter gene sequence. These transporters are useful in the development of drugs by taking advantage of the activity of transporting biological substances and various drugs. It was also found that these transporter genes have single nucleotide polymorphisms (SNP). Gene diagnosis based on the polymorphisms (such as SNP) in these transporter genes enables one to judge, for example, the efficacy of a drug therapy.

    摘要翻译: 通过筛选基于人OATP转运蛋白基因序列的新型转运蛋白基因,成功克隆了四种新型转运蛋白基因。 这些转运蛋白通过利用运输生物物质和各种药物的活性,可用于开发药物。 还发现这些转运蛋白基因具有单核苷酸多态性(SNP)。 基于这些转运蛋白基因多态性(例如SNP)的基因诊断使得人们能够判断药物疗法的功效。

    ORGANIC CATION TRANSPORTER POLYPEPTIDES
    7.
    发明申请
    ORGANIC CATION TRANSPORTER POLYPEPTIDES 审中-公开
    有机载体聚合物

    公开(公告)号:US20120220755A1

    公开(公告)日:2012-08-30

    申请号:US13047399

    申请日:2011-03-14

    IPC分类号: C07K14/435

    CPC分类号: C07K14/47

    摘要: Novel genes significantly homologous to organic cation transporters OCT1 and OCT2 have been successfully isolated by screening a fetal gene library by random sequencing. Proteins encoded by these genes function as transporters of various organic cations.

    摘要翻译: 通过随机测序筛选胎儿基因文库,成功地分离了与有机阳离子转运蛋白OCT1和OCT2显着同源的新基因。 由这些基因编码的蛋白质作为各种有机阳离子的转运体起作用。

    ELECTRONIC SPHYGMOMANOMETER
    9.
    发明申请
    ELECTRONIC SPHYGMOMANOMETER 有权
    电子气泡计

    公开(公告)号:US20110245696A1

    公开(公告)日:2011-10-06

    申请号:US13162278

    申请日:2011-06-16

    IPC分类号: A61B5/0225

    摘要: A power supply unit of an electronic sphygmomanometer includes a dry cell as a primary battery, a rechargeable battery as a secondary battery, and a power supply control circuit. A voltage detector detects a voltage (characteristic value) of the rechargeable battery, and a voltage detector detects the voltage of the dry cell. A switching control unit performs switching control of the dry cell and the rechargeable battery based on a detection result by the voltage detectors.

    摘要翻译: 电子血压计的电源单元包括作为一次电池的干电池,作为二次电池的可再充电电池和电源控制电路。 电压检测器检测可再充电电池的电压(特性值),电压检测器检测干电池的电压。 开关控制单元根据电压检测器的检测结果对干电池和可再充电电池进行开关控制。

    Tissue-specific transporter inhibitor
    10.
    发明授权
    Tissue-specific transporter inhibitor 失效
    组织特异性转运蛋白抑制剂

    公开(公告)号:US07420029B2

    公开(公告)日:2008-09-02

    申请号:US10742335

    申请日:2003-12-19

    IPC分类号: C07K17/00 A61K31/74 C07H1/00

    摘要: The present invention is to provide a tissue-specific transporter inhibitor which is not absorbed through the digestive tract and can prevent deterioration in the QOL of a patient caused by diet therapy, and a therapeutic drug for tissue dysfunction diseases and a therapeutic drug for suppressing the progress of chronic renal failure containing the inhibitor as an active ingredient. A tissue-specific transporter inhibitor which is not absorbed through the digestive tract is constructed by introducing a dipeptide which is a ligand of an oligopeptide transporter 1 into a supramolecular structure polyrotaxane wherein its structurally modified active residue is expected to be excellent in the interaction with a transmembrane transporter.

    摘要翻译: 本发明提供一种组织特异性转运蛋白抑制剂,其不通过消化道吸收,并且可以防止饮食治疗引起的患者生活质量的恶化,以及用于组织功能障碍疾病的治疗药物和用于抑制 含有抑制剂作为活性成分的慢性肾功能衰竭进展。 不通过消化道吸收的组织特异性转运蛋白抑制剂是通过将作为寡肽转运体1的配体的二肽引入超分子结构的聚轮烷而构成的,其中其结构改性的活性残基预期与 跨膜转运蛋白